Scientific Reports · 2018 · 13 citations · 36 references
MedicineNeurologyNeuroscienceGene DeliveryGene TherapyInflammationAxonal DegenerationDemyelinating DiseasesDemyelinating DisordersNerve RegenerationNeurological Gene TherapyNeuroprotectionAdeno-associated Viral TransgenesisAutoimmune Peripheral NeuropathiesChronic Inflammatory Demyelinating PolyradiculoneuropathyGene-targeted TherapyInflammatory DemyelinationInsulin-like Growth Factor-1Peripheral Neuropathy PathophysiologySecondary Degeneration
). SAPP is a chronic progressive and multifocal inflammatory and demyelinating polyneuropathy of spontaneous onset with secondary axonal degeneration. Insulin-like growth factor 1(IGF-1) is a pleiotropic factor with neuroprotective, regenerative, and anti-inflammatory effects with extensive experience in its preclinical and clinical use. Systemic delivery of recombinant adeno-associated virus serotype 9 (rAAV9) provides robust and widespread gene transfer to central and peripheral nervous systems making it suitable for gene delivery in neurological diseases. A significant proportion of patients with inflammatory neuropathies like CIDP do not respond to current clinical therapies and there is a need for new treatments. In this study, we examined the efficacy IGF-1 gene therapy by systemic delivery with rAAV9 in SAPP model. The rAAV9 construct also contained a reporter gene to monitor the surrogate expression of IGF-1. We found significant improvement in neuropathic disease after systemic delivery of rAAV9/IGF-1 gene at presymptomatic and symptomatic stages of SAPP model. These findings support that IGF-1 treatment (including gene therapy) is a viable therapeutic option in immune neuropathies such as CIDP.
36
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Kevin D. Foust, Emily Nurre, Chrystal L. Montgomery et al. · Nature Biotechnology · 2008 · 1.4K citations · Full text